05/12/04 Lung Health StudySlide 1 of 6 Lung Health Study Heavy Smokers Experienced a Greater Benefit in the Reduction of the Decline Rate of their Pulmonary.

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

Hypothesis testing 5th - 9th December 2011, Rome.
Mortality and Access to Care Among Adults After State Medicaid Expansions Benjamin D. Sommers, Katherine Baicker, & Arnold Epstein Harvard School of Public.
Long term effect of self-regulation education on use of inhaled anti-inflammatories and short-acting bronchodilators Clark, NM, Gong, M, Wang, S, Lin,
Aging Farmers: Findings from the UC Davis Farmer Cohort Marc Schenker, Diane Mitchell, Tracey Armitage Western Center for Agricultural Health.
Cross-sectional study. Definition in Dictionary of pharmaceutical medicine 2009 by G Nahler Dictionary of pharmaceutical medicine cross-sectional study.
Outcome of Patients with Advanced Heart Failure who Receive Device- Based Therapy for Primary Prevention of Sudden Cardiac Death, G. Amit, N. Samniah,
ODAC May 3, Subgroup Analyses in Clinical Trials Stephen L George, PhD Department of Biostatistics and Bioinformatics Duke University Medical Center.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
1 Using Biostatistics to Evaluate Vaccines and Medical Tests Holly Janes Fred Hutchinson Cancer Research Center.
Effect of Physician Asthma Education on Health Care Utilization of Children at Different Income Levels Randall Brown, Noreen Clark, Niko Kaciroti, Molly.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.
Journal Club Alcohol and Health: Current Evidence July–August 2004.
Applied Epidemiology Epidemiology of Chronic Obstructive Pulmonary Disease (COPD) By Chris Callan 23 April 2008.
BS704 Class 7 Hypothesis Testing Procedures
Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.
A Longitudinal Study of Maternal Smoking During Pregnancy and Child Height Author 1 Author 2 Author 3.
COPD MANAGEMENT FALLS SHORT AT RCRMC Jean Solomon, M.D.
Women's Health Study: Low-Dose Aspirin in Primary Prevention Presented at American College of Cardiology Scientific Sessions 2005 Presented by Dr. Dr.
Characterization of Self-reported Asthma in Morbidly Obese Women Observational studies have shown obesity to be associated with increased risk of asthma.
Multiple Choice Questions for discussion
6 / 5 / RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 3 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) ALLHAT.
Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.
TEMPLATE DESIGN © Prevalence of educational qualifications and access to information technologies in patients with acute.
Interpretation Normal Spirometry Obstructive pattern Restrictive pattern Mixed pattern Small airway obstruction Non-specific ventilatory pattern Probably.
Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.
The Diabetic Retinopathy Clinical Research Network 5-Year Follow-up of a Randomized Trial Evaluating Ranibizumab Plus Prompt versus Deferred Laser for.
Lecture 17 (Oct 28,2004)1 Lecture 17: Prevention of bias in RCTs Statistical/analytic issues in RCTs –Measures of effect –Precision/hypothesis testing.
1 of 46 MGMT 6970 PSYCHOMETRICS © 2014, Michael Kalsher Michael J. Kalsher Department of Cognitive Science Inferential Statistics IV: Factorial ANOVA.
Practical Missing Data Analysis in SPSS (v17 onwards) Peter T. Donnan Professor of Epidemiology and Biostatistics.
EBC course 10 April 2003 Critical Appraisal of the Clinical Literature: The Big Picture Cynthia R. Long, PhD Associate Professor Palmer Center for Chiropractic.
1 Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2012.
Hypothesis testing Intermediate Food Security Analysis Training Rome, July 2010.
TOBACCO USE & OLDER SMOKERS. OLDER SMOKERS In 2004, 3.7 million people aged 65 and older were smokers and 16% of all people aged 50 and older smoked;
Lung Volume Reduction Surgery and Quality of Life Amy Burker ALHE 4060/ Masini April 22, 2007.
HvC Comparative Effectiveness Project Groups 5 and 6
Focus Area 24 Respiratory Diseases Progress Review June 29, 2004.
Individualization Strategies for Older Patients with Diabetes Elbert S. Huang, MD MPH FACP University of Chicago.
Community based integrated intervention for prevention and management of Chronic Obstructive Pulmonary Disease in Guangdong, China: cluster randomised.
Smoking Data The investigation was based on examining the effectiveness of smoking cessation programs among heavy smokers who are also recovering alcoholics.
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 10 Comparing Two Groups Section 10.1 Categorical Response: Comparing Two Proportions.
Lecture PowerPoint Slides Basic Practice of Statistics 7 th Edition.
Session 6: Other Analysis Issues In this session, we consider various analysis issues that occur in practice: Incomplete Data: –Subjects drop-out, do not.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Efficacy of Combination First Line Agents for Smoking Cessation Sneha Baxi, Pharm.D. Pharmacy Practice Resident University of Illinois at Chicago.
CAPSTONE PROJECT. Setting the scene- why smoking cessation is important in the treatment of COPD.
History Taking Zinc code: UKACL1878ea Date of preparation May 2015 AstraZeneca provided funding & reviewed for technical accuracy.
Approaches to quantitative data analysis Lara Traeger, PhD Methods in Supportive Oncology Research.
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
Daniel B. Jamieson, Elizabeth C. Matsui, Andrew Belli1, Meredith C. McCormack, Eric Peng Simon Pierre-Louis, Jean Curtin-Brosnan, Patrick N. Breysse, Gregory.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.
J R Hurst Thorax : Depart. Of Pulmonology R3 백승숙.
Survival with Cardiac- Resynchronization Therapy in Mild Heart Failure.
Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease Johannes M.A. Daniels; Dominic snijders;
Reducing Tobacco Intake Lowers Risk of Lung Cancer in Heavy Smokers Slideset on: Godtfredsen NS, Prescott E, Osler M. Effect of smoking reduction on lung.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Date of download: 6/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Comparison of Physician-, Biomarker-, and Symptom-Based.
Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.
The Diabetic Retinopathy Clinical Research Network Intravitreal Ranibizumab for Diabetic Macular Edema with Prompt vs Deferred Laser Treatment: 3-year.
From: Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary DiseaseThe REDUCE Randomized Clinical Trial.
Blood eosinophils as a biomarker in alpha 1 antitrypsin deficiency
Types of T-tests Independent T-tests Paired or correlated t-tests
Alcohol, Other Drugs, and Health: Current Evidence May-June, 2018
Local Tobacco Control Profiles The webinar will start at 1pm
Smoking cessation rate as point prevalence quit rate from year 1 to 5 in the Lung Health Study with 5,587 chronic obstructive pulmonary disease patients.
Volume 103, Issue 6, Pages (June 1993)
Volume 154, Issue 6, Pages (December 2018)
D94- COPD: EPIDEMIOLOGY AND THERAPY
Presentation transcript:

05/12/04 Lung Health StudySlide 1 of 6 Lung Health Study Heavy Smokers Experienced a Greater Benefit in the Reduction of the Decline Rate of their Pulmonary Function as a result of LHS Smoking Intervention Program among Males SoonYoung Jang John Connett

05/12/04 Lung Health StudySlide 2 of 6 Chronic obstructive pulmonary disease (COPD) Fourth leading cause of death in the US since 1978 An insidious disease, with a long course of considerable deterioration of pulmonary function before symptoms even develop Lung Health Study (LHS1) Purpose: To determine the effectiveness of an intensive smoking cessation program and the use of inhaled bronchodilator in reducing the rate of decline in pulmonary function Study Population: Smokers, aged 35 to 60 years, with mild obstructive pulmonary disease Randomized Clinical Trial Background i.Ten clinical centers located in North America ii.From October 1986 to April 1994 iii.3,926 participants Total, 64% men Results of the Previous Study Success of the smoking intervention program in slowing down the rate of decline of pulmonary function More rapid rate of decline in lung function for heavy smokers at baseline among continuous smokers High rate of sustained smoking cessation among heavy smokers in LHS Objective To assess whether the effect of the smoking intervention program on the rate of decline of pulmonary function is the same for heavy smokers at baseline and light smokers at baseline, among males.

05/12/04 Lung Health StudySlide 3 of 6 Dataset The first 317 male participants from the original LHS1 dataset Primary Outcome Measure The cumulative change in the percent post-bronchodilator FEV1(forced expiratory volume in 1 second) from baseline, measured at yearly follow-up over a 5 year period Factors of Interest Two levels of Intent-to-treatment group: SI / UC Participation in LHS Smoking Intervention Program (SI) or Usual Care (UC) regardless of bronchodilator therapy status in the original study Two levels of smoking rate group: Heavy / Light Divided according to the median (30 cigs/day) of the participants’ self-reported cigarettes per day consumed at baseline Data Summaries Baseline characteristics by four combination groups Descriptive and graphical summary of the primary outcome over a 5 year period by four combination groups Analysis Four-way mixed effect analysis of variance using repeated measures model multiple pairwise comparisons using Tukey’s adjustment A polynomial contrast to test time trend Pearson chi-sq test for homogeneity of changes in smoking status, determined at the final year, between heavy smokers and light smokers Method

05/12/04 Lung Health StudySlide 4 of 6 Results Missing Response(FEV1) Rate 14.9% (40 out of 1590) Baseline Characteristics Similar distribution of weight and baseline FEV1 across four combination groups Significantly different age between the two smoking rate groups (F(1,314)=9.36, p-value=0.002) Data Summary Observed the slowest decline rate of FEV1 (%) in the SI Heavy smokers group (2.98±0.85) in contrast to the most rapid decline rate of FEV1 (%) in the UC Heavy smokers group (9.80±1.15) Observed no substantial differences between the SI Light smokers and the UC Light smokers groups (5.47±0.83 vs. 5.82±0.94) Suggested a linear Trend of decline with different rate between SI and UC ( Figure 1) Observed slightly more sustained quitters among heavy smokers (30.77% vs %) For sustained quitters, the former heavy smokers found slightly longer time period before quitting compared to the former light smokers (Mean=2.1, sd=1.47 vs. Mean=2.2, sd=1.46) Analysis Results No evidence of nonlinear trend for all groups (p-value > 0.5) Significant interaction between the intent-to-treat factor and the year factor (F(4,1040)=3.5, p-value < 0.01)

05/12/04 Lung Health StudySlide 5 of 6 Analysis Results (Continued) Significantly different effect of LHS smoking intervention program on the mean % change in FEV1 by smoking rate group (F(1,301)=13.81, p-value = ) No significant effect of the baseline smoking rate group when averaged across the two intent-to-treatment groups (F(1,301)=0.60, p-value>0.4) The slowest decline rate was observed in the SI heavy smokers group (3.29±1.47), and it significantly differed from all others. Significant participant-to-participant variability (48.18±8.88)

05/12/04 Lung Health StudySlide 6 of 6 Discussion Hypothesis: Expect the same or more rapid decline for heavy smokers compared to light smokers in the smoking intervention program NOT TRUE !! Why ? Unanswered Similar distribution of Sustained, Intermittent & Continuous smokers determined at the end of the study Similar % of cigarettes/day reduction Participants in the program were similar in age Similar in baseline FEV1 despite different smoking rate => related to airway hyper-responsiveness ? Shortcomings Post-hoc analysis of clinical trials data Voluntary based recruitment in the original study Measurement (Self-reported smoking rate, Raw FEV1) Specific to the LHS smoking intervention program Summary Greater benefit of the smoking intervention program on reducing the decline rate of pulmonary function among heavy male smokers Practical Implication An intensive and effectively organized smoking intervention program could help male heavy smokers prevent or delay the advance of severe COPD.